share_log

XORTX Therapeutics | 6-K/A: Report of foreign private issuer (related to financial reporting)

XORTX Therapeutics | 6-K/A: Report of foreign private issuer (related to financial reporting)

XORTX Therapeutics | 6-K/A:外國發行人報告(業績相關)
美股SEC公告 ·  2024/09/13 12:51

Moomoo AI 已提取核心訊息

XORTX Therapeutics has filed an amended MD&A for Q2 2024, providing additional details on funding allocations for its product development programs. The company plans to allocate 98% of available funds to advance XRx-008 for ADPKD treatment, with 1% each for XRx-101 and XRx-225 programs.The company reported Q2 2024 net income of $170,066 versus a loss of $1.69M in Q2 2023, primarily due to reduced R&D expenses of $67,683 compared to $667,913 last year. As of June 30, 2024, XORTX had cash of $3.08M and working capital of $1.26M. The company raised CAD $2.7M through unit offerings in Q1 2024.XORTX's lead program XRx-008 is advancing toward Phase 3 registration trials, with plans to initiate the XRX-OXY-201 trial in H1 2025 pending funding. The company estimates costs of $5-30M for XRX-OXY-201 and additional funds needed for CMC work, commercialization studies and European registration activities through 2027.
XORTX Therapeutics has filed an amended MD&A for Q2 2024, providing additional details on funding allocations for its product development programs. The company plans to allocate 98% of available funds to advance XRx-008 for ADPKD treatment, with 1% each for XRx-101 and XRx-225 programs.The company reported Q2 2024 net income of $170,066 versus a loss of $1.69M in Q2 2023, primarily due to reduced R&D expenses of $67,683 compared to $667,913 last year. As of June 30, 2024, XORTX had cash of $3.08M and working capital of $1.26M. The company raised CAD $2.7M through unit offerings in Q1 2024.XORTX's lead program XRx-008 is advancing toward Phase 3 registration trials, with plans to initiate the XRX-OXY-201 trial in H1 2025 pending funding. The company estimates costs of $5-30M for XRX-OXY-201 and additional funds needed for CMC work, commercialization studies and European registration activities through 2027.
XORTX治療公司已提交2024年第二季度的修訂MD&A,提供了關於產品開發項目資金分配的更多細節。公司計劃將98%的可用資金用於推進XRx-008治療ADPKD,XRx-101和XRx-225項目各佔1%。公司報告2024年第二季度的凈利潤爲170,066美元,而2023年第二季度則虧損169萬美元,主要由於研發費用減少67,683美元,而去年爲667,913美元。截至2024年6月30日,XORTX的現金爲308萬美元,運營資本爲126萬美元。公司在2024年第一季度通過單位發行融資270萬加元。XORTX的主導項目XRx-008正在向第三階段註冊試驗推進,計劃在2025年上半年啓動XRX-OXY-201試驗,待資金到位。公司估計XRX-OXY-201的費用在500萬到3000萬之間,並需要額外資金用於CMC工作、商業化研究及2027年前的歐洲註冊活動。
XORTX治療公司已提交2024年第二季度的修訂MD&A,提供了關於產品開發項目資金分配的更多細節。公司計劃將98%的可用資金用於推進XRx-008治療ADPKD,XRx-101和XRx-225項目各佔1%。公司報告2024年第二季度的凈利潤爲170,066美元,而2023年第二季度則虧損169萬美元,主要由於研發費用減少67,683美元,而去年爲667,913美元。截至2024年6月30日,XORTX的現金爲308萬美元,運營資本爲126萬美元。公司在2024年第一季度通過單位發行融資270萬加元。XORTX的主導項目XRx-008正在向第三階段註冊試驗推進,計劃在2025年上半年啓動XRX-OXY-201試驗,待資金到位。公司估計XRX-OXY-201的費用在500萬到3000萬之間,並需要額外資金用於CMC工作、商業化研究及2027年前的歐洲註冊活動。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息